Scale-up of radiotherapy for cervical cancer
Menée à l'aide d'une modélisation, cette étude estime, sur la période 2015-2035 pour les pays à revenu faible ou intermédiaire, le nombre de femmes nécessitant une radiothérapie externe en combinaison ou non avec une curiethérapie pour traiter un cancer du col utérin, et les bénéfices, en termes de pourcentage de réduction de l'incidence de la maladie, du nombre d'années de vie gagnées et de retour sur investissements, d'une augmentation de l'utilisation de la radiothérapie dans le contexte d'une politique de vaccination contre le papillomavirus humain ciblant les adolescentes de 12 ans
Cervical cancer is the fourth most common cancer among women globally, with an estimated 570 000 new cases and 311 000 deaths worldwide in 2018. 1
The incidence is especially high in low-income and middle-income countries, where about 85% of all global cases of locally advanced cervical cancer are detected and where sufficient resources, especially radiotherapy facilities, are scarce or unavailable. 2
The situation is compounded by high burdens in rural areas, where access to health care is especially challenging. 3
With all the international organisations and bodies (ie, WHO, the United Nations, the International Agency for Research on Cancer, the Union for International Cancer Control, and the International Atomic Energy Agency) working towards the elimination (prevention, screening, and treatment) of cervical cancer, the Article by Danielle Rodin and colleagues 4
in The Lancet Oncology, which addresses the effects of upscaling radiotherapy facilities, is very important and relevant, especially in the context of the global drive for scale-up of human papillomavirus (HPV) vaccination.
The Lancet Oncology , commentaire, 2018